Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to improving the lives of patients and families suffering from seizures, depression and other neuropsychiatric disorders. Our lead clinical stage drug candidate, ganaxolone, brings a new GABAA receptor modulating mechanism and an extensive safety database with exhibited anxiolytic, anti-seizure and anesthetic activity.Marinus is developing three different convenient dose forms of ganaxolone (IV, capsule, and liquid) to maximize the therapeutic reach to adult and pediatric patients in both acute and chronic care settings where there is a mechanistic rationale for ganaxolone to provide a benefit.
|Bank Name||Marinus Pharmaceuticals, Inc.|
|Chairman||Mr. Christopher Michael Cashman|
|CEO||Mr. Christopher Michael Cashman|